After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
NewAmsterdam Pharma Company NV is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of NewAmsterdam Pharma Company NV is $2.75B. A total of 0.71 million shares were traded on the day, compared to an average of 862.52K shares.
In the most recent transaction, Topper James N bought 471 shares of NAMS for 23.98 per share on Aug 11 ’25. After the transaction, the Director now owns 3,026,604 company shares. In a previous transaction on Jul 16 ’25, Kling Douglas F sold 51,043 shares at 21.10 per share. NAMS shares that Chief Operating Officer owns now total 44,000.
Among the insiders who sold shares, Kling Douglas F disposed of 47,569 shares on Jul 15 ’25 at a per-share price of $21.44. This resulted in the Chief Operating Officer holding 44,000 shares of NAMS after the transaction. In another insider transaction, NAP PoolCo B.V. bought 1,433,193 shares at $21.56 per share on Jul 14 ’25.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, NAMS has a high of $27.29 and a low of $14.06.
As of this writing, NAMS has an earnings estimate of -$0.36 per share for the current quarter. EPS was calculated based on a consensus of 11.0 estimates, with a high estimate of -$0.24 per share and a lower estimate of -$0.44. The company reported an EPS of -$0.16 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. NAMS’s latest balance sheet shows that the firm has $60.11M in Cash & Short Term Investments as of fiscal 2021. There were $185.68k in debt and $11.19M in liabilities at the time. Its Book Value Per Share was $6.92, while its Total Shareholder’s Equity was $56.37M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NAMS is Buy with a score of 4.57.
